Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229.
Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH.
AJR Am J Roentgenol. 2024 Jan;222(1):e2329640. doi: 10.2214/AJR.23.29640. Epub 2023 Aug 2.
The Fontan operation palliates single-ventricle congenital heart disease but causes hepatic congestion with associated progressive hepatic fibrosis. The purpose of this study was to evaluate associations between liver stiffness measured using ultrasound (US) shear-wave elastography (SWE) in patients with Fontan palliation and the occurrence of portal hypertension and Fontan circulatory failure during follow-up. This retrospective study included 119 individuals 10 years old or older (median age, 19.1 years; 61 female patients, 58 male patients) with Fontan circulation who underwent liver US with 2D SWE from January 1, 2015, to January 1, 2022, and had 1 year or more of clinical follow-up (unless experiencing earlier outcome-related events). Median liver stiffness from the initial US examination was documented. Varices, ascites, splenomegaly, and thrombocytopenia (VAST) scores (range, 0-4) were determined as a marker of portal hypertension on initial US examination and 1 year or more of follow-up imaging (US, CT, or MRI). Composite clinical outcome for Fontan circulatory failure (death, mechanical circulatory support, cardiac transplant, or unexpected Fontan circulation-related hospitalization) was assessed. Analysis included the Wilcoxon rank sum test, logistic regression analysis with stepwise variable selection, and ROC analysis. Median initial liver stiffness was 2.22 m/s. Median initial VAST score was 0 (IQR, 0-1); median follow-up VAST score was 1 (IQR, 0-2) ( = .004). Fontan circulatory failure occurred in 37 of 119 (31%) patients (median follow-up, 3.4 years). Initial liver stiffness was higher in patients with a follow-up VAST score of 1 or greater (2.37 m/s) than in those with a follow-up VAST score of 0 (2.08 m/s) ( = .005), and initial liver stiffness was higher in patients with (2.43 m/s) than without (2.10 m/s) Fontan circulatory failure during follow-up ( < .001). Initial liver stiffness was the only significant independent predictor of Fontan circulatory failure (OR = 3.76; < .001); age, sex, Fontan operation type, dominant ventricular morphology, and initial VAST score were not independent predictors. Initial liver stiffness had an AUC of 0.70 (sensitivity, 79%; specificity, 57%; threshold, > 2.11 m/s) for predicting a follow-up VAST score of 1 or greater and an AUC of 0.74 (sensitivity, 84%; specificity, 52%; threshold, > 2.12 m/s) for predicting Fontan circulatory failure. In patients with Fontan circulation, increased initial liver stiffness was associated with portal hypertension and circulatory failure during follow-up, although it had moderate performance in predicting these outcomes. US SWE may play a role in post-Fontan surveillance, supporting tailored medical and surgical care.
Fontan 手术姑息治疗单心室先天性心脏病,但会导致肝充血和相关的进行性肝纤维化。本研究的目的是评估 Fontan 姑息治疗患者的超声(US)剪切波弹性成像(SWE)测量的肝脏硬度与随访期间门静脉高压和 Fontan 循环衰竭的发生之间的关联。这项回顾性研究纳入了 119 名年龄在 10 岁或以上(中位年龄 19.1 岁;61 名女性患者,58 名男性患者)的 Fontan 循环患者,这些患者在 2015 年 1 月 1 日至 2022 年 1 月 1 日期间接受了肝脏 US 和二维 SWE 检查,并进行了 1 年或更长时间的临床随访(除非发生更早的与结局相关的事件)。记录了初始 US 检查的中位肝脏硬度。在初始 US 检查和 1 年或更长时间的随访影像学(US、CT 或 MRI)上确定了门静脉高压的标志物包括静脉曲张、腹水、脾肿大和血小板减少(VAST)评分(范围 0-4)。Fontan 循环衰竭的复合临床结局(死亡、机械循环支持、心脏移植或意外的 Fontan 循环相关住院治疗)被评估。分析包括 Wilcoxon 秩和检验、逐步变量选择的逻辑回归分析和 ROC 分析。中位初始肝脏硬度为 2.22 m/s。中位初始 VAST 评分为 0(IQR,0-1);中位随访 VAST 评分为 1(IQR,0-2)( =.004)。119 名患者中有 37 名(中位随访时间 3.4 年)发生了 Fontan 循环衰竭。随访 VAST 评分≥1 的患者的初始肝脏硬度(2.37 m/s)高于 VAST 评分=0 的患者(2.08 m/s)( =.005),而随访中有(2.43 m/s)Fontan 循环衰竭的患者的初始肝脏硬度高于无(2.10 m/s)Fontan 循环衰竭的患者( <.001)。初始肝脏硬度是 Fontan 循环衰竭唯一显著的独立预测因素(OR=3.76; <.001);年龄、性别、Fontan 手术类型、优势心室形态和初始 VAST 评分不是独立预测因素。初始肝脏硬度对预测随访时 VAST 评分≥1 的 AUC 为 0.70(敏感性 79%,特异性 57%,阈值>2.11 m/s),对预测 Fontan 循环衰竭的 AUC 为 0.74(敏感性 84%,特异性 52%,阈值>2.12 m/s)。在 Fontan 循环患者中,初始肝脏硬度的增加与随访期间的门静脉高压和循环衰竭有关,尽管其在预测这些结局方面的表现中等。US SWE 可能在 Fontan 术后监测中发挥作用,支持量身定制的医疗和手术护理。